Table 2

Coagulation parameters during the study

At baseline

After bolus application

At end of treatment period

Placebo

Antithrombin

Placebo

Antithrombin

Placebo

Antithrombin

Prothrombin time (%)

70 (38–95)

60 (38–103)

60 (39–84)

60 (38–82)

77 (5–10)

64 (5–9)

Activated partial thromboplastin time (s)

42 (27–53)

46 (33–60)

44 (32–67)

53 (34–77)

44 (29–74)

47 (34–95)

Fibrinogen (mg/dl)

587 (262–821)

557 (229–841)

595 (283–770)

505 (313–704)

622 (115–842)

538 (200–868)

Platelet count (1,000/ml)

225 (86–581)

179 (71–742)

170 (81–358)

154 (61–730)

199 (63–418)

115 (14–475)

Antithrombin (%)

68 (31–113)

55 (27–99)

54 (22–108)

110* (43–350)

86 (29–87)

141* (110–149)

Reaction time (mm)

7 (6–15)

9 (6–16)

8 (5–15)

11 (7–25)

8 (5–19)

11 (8–18)

Coagulation time (mm)

3 (2–4)

3 (2–8)

3 (2–4)

3 (2–7)

2 (1–8)

4 (3–10)

Alpha angle (°)

74 (64–80)

71 (50–80)

69 (64–81)

70 (36–79)

76 (43–81)

64 (46–76)

Maximum amplitude (mm)

69 (57–79)

66 (49–81)

66 (60–74)

70 (49–83)

71 (38–82)

72 (38–82)

Abciximab maximum amplitude (mm)

29 (15–49)

29 (13–49)

29 (23–45)

28 (12–45)

33 (14–48)

31 (7–48)

Data presented as the median (minimum–maximum). Normal ranges: prothrombin time = 75–140%, activated partial thromboplastin time = 27–41 s, reaction time = 10–19 mm, coagulation time = 4–10 mm, alpha angle = 44–56°, maximum amplitude = 50–64 mm. *P ≤ 0.05 compared with placebo.

Gonano et al. Critical Care 2006 10:R160   doi:10.1186/cc5098